Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1411-1425

  Chopra, Puneet ^a   Kanoje, Vijay ^a   Semwal, Arvind ^a   Ray, Abhijit ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Arthritis; Inflammation; Inhalation; Kinases; MAPKs; p38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADALIMUMAB; AMG 548; ARRY 371797; BRONCHODILATING AGENT; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYCLOOXYGENASE 2; DORAMAPIMOD; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PLACEBO; PROTEIN SERINE THREONINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SCIO 469; SD 282; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOSYNTHESIS; CARDIOTOXICITY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFLAMMATION; LIVER TOXICITY; LOW DRUG DOSE; METERED DOSE INHALER; MONOTHERAPY; MORTALITY; NONHUMAN; OSTEOLYSIS; PATHOGENESIS; PNEUMONIA; POWDER INHALER; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RNA STABILITY; RNA TRANSLATION; SIDE EFFECT; TRANSCRIPTION REGULATION;

ADMINISTRATION, INHALATION; ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; ASTHMA; CELL CYCLE; CELL DIFFERENTIATION; CELL MOVEMENT; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 52949154357     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1411     Document Type: Review

References (99)

1. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26
2. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83
3. Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 1999;162:4246-52
4. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-7
5. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999;1:94-7
6. Mudgett JS, Ding J, Guh-Siesel L, et al. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000;97:10454-9
7. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998;273:32111-20
8. Zetser A, Gredinger E, Bengal E. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J Biol Chem 1999;274:5193-200
9. Li Y, Jiang B, Ensign WY, et al. Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell Signal 2000;12:751-7
10. Wu Z, Woodring PJ, Bhakta KS. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol 2000;20:3951-64
11. Suelves M, Lluis F, Ruiz V, et al. Phosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes. EMBO J 2004;23:365-75
12. De Angelis L, Zhao J, Andreucci JJ, et al. Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. Dev Biol 2005;283:171-9
13. Jones NC, Tyner KJ, Nibarger L, et al. The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J Cell Biol 2005;169:105-16
14. Ziegler-Heitbrock HW, Blumenstein M, Käfferlein E, et al. In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology 1992;75:264-8
15. Molnár A, Theodoras AM, Zon LI, Kyriakis JM. Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK. J Biol Chem 1997;272:13229-35
16. Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 1998;280:599-602
17. Shiozaki K, Russell P. Cell-cycle control linked to extracellular environment by MAP kinase pathway in fission yeast. Nature 1995;378:739-43
18. Kummer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1997;272:20490-4
19. Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31
20. Juo P, Kuo CJ, Reynolds SE, et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 1997;17:24-35
21. Cahill MA, Peter ME, Kischkel FC, et al. CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene 1996;13:2087-96
22. Cardone MH, Salvesen GS, Widmann C, et al. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997;90:315-23
23. Huang S, Jiang Y, Li Z, et al. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 1997;6:739-649
24. Schwenger P. Bellosta R Vietor I, et al. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997;94:2869-73
25. Kawasaki H, Morooka T, Shimobama S, et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 1997;272:18518-21
26. Yue TL, Ni J, Romanic AM, et al. TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 1999;274:1479-86
27. Rousseau S Houle F, Landry J, Huot J. p38 MAP Inase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77
28. Heir B, Tavener S, Raharjo E, Kubes P. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol 2002;159:91-102
29. Heuertz RM, Tricomi SM, Ezekiel UR, Webster RO. C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement. J Biol Chem 1999;274:17968-74
30. Ishizuka T, Okajima F, Ishiwara M, et al. Sensitized mast cells migrate toward the antigen: a response regulated by p38 mitogenactivated protein kinase and Rho-associated. coiled-coil-forming protein kinase. J Immunal 2001;167:2298-304
31. Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway, Cell Signal 2006;18:1897-905
32. Hedges JC, Dechert MA, Yamboliev IA, et al. A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem 1999;274:24211-9
33. Piotrowicz RS, Hickey E, Levin EG. Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration. FASEB J 1998;12:481-90
34. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998;58:1135-9
35. Simon C, Simon M, Vucelic G, et al. The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exo Cell Res 2001;271:344-55
36. Woo CH, Lim JH, Kim JH, Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. J Immunol 2004:173:6973-80
37. Nguyen J, Gogusev J, Knapnougel P, Bauvois B. Protein tyrosine kinase and p38 MAP kinase pathways are involved in stimulation of matrix metalloproteinase-9 by TNF-alpha in human monocytes. Immunol Lett 2006; 106:34-41
38. Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Inummol 2002;3:69-75
39. Soloaga A, Thomson S, Wiggin GR, et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 2003;22:2788-97
40. Perregaux DG, Dean D, Cronan M, et al. Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol Pharmacol 1995;48:433-42
41. Guan Z, Buckman SY, Pentland AP, et al. Induction of Cyclooxygenase-2 by the Activated Mekk1-] Sekl/Mkk4-]P38 Mitogen-Activated Protein Kinase Pathway. J Biol Chem 1998;273:12901-8
42. Badger AM, Cook MN, Lark MW et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998; 161:467-73
43. Feng GJ, Goodridge HS, Harnett MM, et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 1999;163:6403-12
44. Clark AR, Dean JL, Saklarvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003;546:37-44
45. Reunanen N, Li SP, Ahonen M, et al. Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 2002;277:32360-8
46. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12
47. Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17;811-29
48. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5
49. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-31
50. Wei S, Kitaura H, Zhou P. et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-90
51. Matsumoto M, Sudo T, Saito T, et al. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000;275:31155-61
52. Foster ML, Halley F, Souness JE. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect 2000; 13:488-97
53. Branger J, Van Den Blink B, Weijer S, et al. Antiinflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002;168:4070-7
54. Barnes PJ. Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease Am. J Respir Crit Care Med 1999;160:S72-9
55. Elias JA, Lee CG, Zheng T, et al. New insights into the pathogenesis of asthma. J Clin Invest 2003; 111:291-7
56. Herrick CA, Bottomly K. To respond or not to respond: t cells in allergic asthma. Nat Rev Immunol. 2003;3:405-12
57. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999;51:213-340
58. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002;2:773-86
59. Adachi T, Choudhury BK, Stafford S, et al. The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000;165:2198-204
60. Wong CK, Ip WK, Larn CW. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor-induced adhesion molecule expression on eosinophils by p38 mitogen-activated protein kinase and nuclear factor- [kappa] B. Am J Respir Cell Mol Biol 2003;29:133-47
61. Hallsworth MP, Moir LM, Lai D, Hirst SJ. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth mustle. Am J Respir Crit Care Med 2001;164:688-9
62. Underwood DC, Osborn RR, Bochnowicz; S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L895-902
63. Duan W, Chan JH, McKay K, et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005;171:571-8
64. Available from: http://www.arraybiopharma.com
65. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2
66. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-9
67. Underwood DC, Osborn RR, Kotzer CJ, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000;293:281
68. Medicherla S, Fitzgerald MF, Spicer D, et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway infl ammation. J Pharmacol Exp Ther 2008;324:921-9
69. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13
70. Tibbles LA, Woodgett JR. The Stress-activated protein kinase pathways. Cell Mol Life Sci 1999;55:1230-54
71. Van Den Blink B, Juffermans NP, Ten Hove T, et al. p38 Mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J Immunol 2001;166:582-7
72. Lehner MD, Schwoebel F, Kotlyarov A, et al. Mitogen-activated protein kinase-activated protein kinase-2 deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol 2002;168:4667-73
73. Culy CR, Keating GM. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis, and juvenile rheumatoid arthritis. Biodrugs 2003;17:139-45
74. Kavanaugh A, Cush JJ. FDA meeting: update on the safety of new drugs for rheumatoid arthritis. Part II. Chf, infection, and other safety issues. Hotline August 2003, Available from: http://www.rheumatology.org/ publications/hotlin
75. Centrella M, McCarthy TL, Canalis E, et al. Mitogenesis in fetal rat bone cells simultaneously exposed to type beta transforming growth factor and other growth regulators. FASEB J 1987;1:312-7
76. Zhen X, Wei L, Wu Q, et al. Mitogen-activated protein kinase p38 mediates regulation of chrondrocyte differentiation by parathyroid hormone. J Bio Chem 2001;272:4879-85
77. Guicheux J, Lemonnier J, Ghayor C, et al. Activation of p38 mitogen-activated protein kinase and c-jun-nh2-terminal kinase by bmp2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-8
78. Wride MA, Sanders EJ. Potential roles for tumor necrosis factor alpha during embryonic development. Anat Embryol 1995;191:1-10
79. Hill JA. Cytokines considered critical in pregnancy. Am J Reprod Immunol 1992;28:123-6
80. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-jun n-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;83:345-52
81. Ravingerova T, Barancik M, Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003;247:127-38
82. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99:1685-91
83. Lemke LE, Bloem LJ, Fouts R, et al. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 mapk alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol 2001;33:1527-40
84. Liang Q, Molkentin JD. Redefining the roles of p38 and Jnk signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 2003;35:1385-94
85. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
86. Behr TM, Berova M, Doe CP, et al. p38 Mitogen-Activated Protein Kinase Inhibitors for the Treatment of Chronic Cardiovascular Disease. Curr Opin Invest Drugs 2003;4:1059-64
87. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38a protein. Curr Med Chem 2005;12;2979-94
88. Hynes J, Leftheris K. Small molecule p38 inhibitors: novel structure features and advances from 2002-2005. Curr Top Med Chem 2005;5:967-85
89. Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of p38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 2005;5:1017-29
90. Wrobleski ST, Doweyko AM. Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions. Curr Top Med Chem 2005;5:1005-16
91. Allen M, Svensson L. Deficiency of the stress kinase 38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000;191:859-70
92. Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5:929-39
93. Everard ML, Hardy JG, Milner AD. Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 1993;48:1045-6
94. Scheuch G, Stahlhofen W. Deposition and dispersion of aerosols in the airways of the human respiratory tract: the effect of particle size. Exp Lung Res 1992;18:343-58
95. Ahrens RC, Ries RA, Popendorf W, Wiese JA. The delivery of therapeutic aerosols through endotracheal tubes. Pediatr Pulmonol 1986;2:19-26
96. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: An update. Pharmacol Rev 1998;50:515-96
97. Bond JA. Metabolism and elimination of inhaled drugs and airborne chemicals from the lungs. Pharmacol Toxicol 1993;72:36-47
98. Reed CJ. Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev 1993;25:173-205
99. Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 1993;23:343-69